✉ Email this page to a colleague
« Back to Dashboard
MT-1303 is an investigational drug.
There have been 12 clinical trials for MT-1303. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation, Bausch Health Americas, Inc., and [disabled in preview].
Recent Clinical Trials for MT-1303
|Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis||Bausch Health Americas, Inc.||Phase 2|
|Extension Study of MT-1303 in Subjects With Crohn's Disease||Mitsubishi Tanabe Pharma Corporation||Phase 2|
|Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease||Mitsubishi Tanabe Pharma Corporation||Phase 2|